InvestorsHub Logo
Followers 48
Posts 5519
Boards Moderated 0
Alias Born 09/04/2009

Re: north40000 post# 266339

Wednesday, 04/15/2020 9:57:19 AM

Wednesday, April 15, 2020 9:57:19 AM

Post# of 430569
North, you raise a great point. There's an overlap between the TG>500 and REDUCE-IT patients, just picture two overlapping circles in a Venn Diagram. So prescribing TG>500 could infringe R-I patents. As a result, FDA shouldn't approve any ANDA.

Dr. Bhatt said there are patients with TG>500 in R-I:

https://ars.els-cdn.com/content/image/1-s2.0-S0735109719357146-gr1.jpg

See his tweets on April 4th.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News